Mepolizumab Dosage
Medically reviewed by Drugs.com. Last updated on Oct 21, 2020.
Applies to the following strengths: 100 mg; 100 mg/mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Asthma - Maintenance
100 mg subcutaneously every 4 weeks
Comments:
-This drug should be administered in the upper arm, thigh, or abdomen.
Use: Add-on maintenance treatment for severe asthma with an eosinophilic phenotype
Usual Adult Dose for Wegener's Granulomatosis
300 mg (as 3 separate 100 mg injections) subcutaneously every 4 weeks
Comments:
-This drug should be administered in the upper arm, thigh, or abdomen as 3 separate 100 mg injections at least 5 cm (approximately 2 inches) apart if more than 1 injection is administered at the same site.
Use: For eosinophilic granulomatosis with polyangiitis (EGPA)
Usual Pediatric Dose for Asthma - Maintenance
6 to 12 years:
40 mg subcutaneously every 4 weeks
12 years or older:
100 mg subcutaneously every 4 weeks
Comments:
-This drug should be administered in the upper arm, thigh, or abdomen.
Use: Add-on maintenance therapy for severe asthma with an eosinophilic phenotype in children 6 years and older
Renal Dose Adjustments
No adjustment recommended.
Liver Dose Adjustments
No adjustment recommended.
Precautions
CONTRAINDICATIONS:
-Hypersensitivity to the active component or any of the ingredients
Safety and efficacy have not been established in patients younger than 6 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
-This drug should be reconstituted and administered by a health care provider.
-Discard if cloudy, milky, or particulate matter remains in solution after reconstitution.
-Subcutaneous administration in upper arm, thigh, or abdomen is preferred.
Storage requirements:
-Lyophilized powder: Protect from light; do not freeze.
-Reconstituted solution: Do not freeze; discard if not used within 6 to 8 hours of reconstitution.
Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.
General:
-This drug should not be used to treat other eosinophilic conditions, acute asthma, bronchospasm, or status asthmaticus.
-Avoid decreasing or discontinuing corticosteroids during initiation of this drug.
-This drug may interfere with helminth infections.
-Hypersensitivity reactions may occur up to days after administration.
-This drug should be prescribed by healthcare professionals experienced in the diagnosis and treatment of severe asthma.
Monitoring:
-Signs and symptoms of uncontrolled or worsening asthma
-Signs and symptoms of an allergic reaction (e.g., facial swelling, rash, hypotension, hives)
Patient advice:
-Warn patients to avoid interruptions or abrupt discontinuation of corticosteroids.
-Instruct patients to notify their healthcare provider upon signs and symptoms of worsening asthma or allergic reaction.
-Patients should be advised to speak to their healthcare provider if pregnant, intend to become pregnant, or are breastfeeding.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Frequently Asked Questions
- How long does it take for Nucala to work?
- Can Nucala cause weight gain?
- Can Nucala be self-administered?
- What is Nucala (mepolizumab) used for and how is it given?
More about mepolizumab
- Side Effects
- During Pregnancy or Breastfeeding
- En Español
- 52 Reviews
- Drug class: interleukin inhibitors
Consumer resources
- Mepolizumab
- Mepolizumab Subcutaneous (Advanced Reading)
- Mepolizumab Auto-Injectors and Prefilled Syringes
- Mepolizumab Vials
Other brands: Nucala